The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory multiple myeloma. The indication is granted for iberdomide combined with standard treatment (daratumumab + dexamethasone – IberDd). The Prescription Drug User Fee Act date is Aug. 17, 2026. Other FDA Actions on Iberdomide According to data currently received, the FDA has additionally granted Breakthrough Therapy designation for iberdomide in this indication. Al...